A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)

NCT07294365 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Immune Thrombocytopenia (ITP)

Interventions

DRUG: DZD8586 dose level 1
DRUG: DZD8586 dose level 2
DRUG: DZD8586 dose level 3

Sponsor

Dizal Pharmaceuticals